MaxCyte FY2022 total revenue $44.3M (+31% YoY); net loss $23.6M

MAXCYTE, INC.

Q4 2022 revenue $12.4M (+22% YoY); core revenue $10.6M (+4%); gross margin 88%.
Full-year core business revenue $39.6M, up 26%; cell therapy segment grew 33%.
Net loss $23.6M vs $19.1M; EBITDA loss $24.8M; cash and equivalents $227.3M.
18 active SPL partnerships; potential pre-commercial milestones >$1.55B.
2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program revenue ~$6M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAXCYTE, INC. updated its the quarter and year ended December 31, 2022 guidance (initiated).

Period: the quarter and year ended December 31, 2022
Guidance: initiated
Result: reported results

Exact text from the filing

On March 15, 2023, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. This press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-003872

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.